CorMedix (CRMD) to Release Earnings on Thursday

CorMedix (NASDAQ:CRMD) will post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect CorMedix to post earnings of ($0.27) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

CorMedix (NASDAQ:CRMD) last issued its earnings results on Tuesday, March 12th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). On average, analysts expect CorMedix to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CorMedix Stock Performance

NASDAQ CRMD opened at $5.84 on Wednesday. The stock has a market capitalization of $320.10 million, a P/E ratio of -6.35 and a beta of 1.79. The business’s fifty day moving average is $4.57 and its two-hundred day moving average is $3.81. CorMedix has a 1 year low of $2.57 and a 1 year high of $7.00.

Insider Buying and Selling

In related news, CEO Joseph Todisco acquired 13,561 shares of the company’s stock in a transaction on Wednesday, March 13th. The shares were purchased at an average price of $3.74 per share, for a total transaction of $50,718.14. Following the purchase, the chief executive officer now owns 352,839 shares in the company, valued at $1,319,617.86. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

CRMD has been the topic of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price target on shares of CorMedix in a research note on Tuesday, April 9th. JMP Securities restated a “market outperform” rating and issued a $19.00 price target on shares of CorMedix in a research report on Tuesday, April 9th. Truist Financial lowered their price objective on shares of CorMedix from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, January 31st. Finally, Royal Bank of Canada decreased their target price on CorMedix from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, March 13th.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.